The Tower of Babel of liver metastases from colorectal cancer: Are we ready for one language?

Critical Reviews in Oncology/Hematology

Volumn 85, Issue 3, 2013, Pages 332-341

  Bittoni, Alessandro ^a   Scartozzi, Mario ^a   Giampieri, Riccardo ^a   Faloppi, Luca ^a   Maccaroni, Elena ^a   Del Prete, Michela ^a   Bianconi, Maristella ^a   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Chemotherapy; Colorectal cancer; Liver metastases; Surgery; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG RESPONSE; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; LIVER SURGERY; LIVER VENOOCCLUSIVE DISEASE; METASTASIS RESECTION; NONALCOHOLIC FATTY LIVER; OVERALL SURVIVAL; PATIENT SELECTION; PERIOPERATIVE PERIOD; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REVIEW; SCORING SYSTEM; TREATMENT DURATION; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS;

EID: 84873526851     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.08.005     Document Type: Review

References (39)

1. Abdalla E.K., Vauthey J.N., Ellis L.M., et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Annals of Surgery 2004, 239:818-827.
2. Fernandez F.G., Drebin J.A., Linehan D.C., et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Annals of Surgery 2004, 240:438-450.
3. Wicherts D.A., de Haas R.J., Adam R. Bringing unresectable liver disease to resection with curative intent. European Journal of Surgical Oncology 2007, 33(Suppl. 2):S42-S51.
4. Fong Y., Cohen A.M., Fortner J.G., et al. Liver resection for colorectal metastases. Journal of Clinical Oncology 1997, 15:938-946.
5. Petrelli N.J. Perioperative or adjuvant therapy for resectable colorectal hepatic metastases. Journal of Clinical Oncology 2008, 26:4862-4863.
6. Fong Y., Fortner J., Sun R.L., et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Annals of Surgery 1999, 230(September (3)):309-318.
7. Tomlinson J.S., Jarnagin W.R., DeMatteo R.P., et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. Journal of Clinical Oncology 2007, 25(October (29)):4575-4580.
8. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371:1007-1016.
9. Nordlinger B., Van Cutsem E., Gruenberger T., et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Annals of Oncology 2009, 20:985-992.
10. Nordlinger B., Sorbye H., Glimelius B., et al. EORTC liver metastases intergroup randomized phase III study 40983: long-term survival results. Journal of Clinical Oncology 2012, 30(Suppl.). [Abstract 3508].
11. Gruenberger B., Tamandl D., Schueller J., et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. Journal of Clinical Oncology 2008, 26:1830-1835.
12. Folprecht G., Grothey A., Alberts S., et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Annals of Oncology 2005, 16(August (8)):1311-1319.
13. Tournigand C., André T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of Clinical Oncology 2004, 22(January (2)):229-237.
14. Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. Journal of Clinical Oncology 2007, 25:1670-1676.
15. Ychou M., Viret F., Kramar A., et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemotherapy and Pharmacology 2008, 62(July (2)):195-201.
16. Van Cutsem E., Rivera F., Berry S., et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Annals of Oncology 2009, 20:1842-1847.
17. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of Clinical Oncology 2008, 26:2013-2019.
18. Van Cutsem E., Kohne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New England Journal of Medicine 2009, 360:1408-1417.
19. Bokemeyer C., Bondarenko I., Hartmann J.T., et al. Biomarkers predictive for outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line FOLFOX4 plus or minus cetuximab: updated data from the OPUS study. Gastrointestinal Cancers Symposium 2010, [Abstract 428].
20. Folprecht G., Gruenberger T., Bechstein W.O., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncology 2010, 11:38-47.
21. Langer B., Bleiberg H., Labianca R., et al. Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proceedings of the American Society of Clinical Oncology 2002, 21(Suppl.):149a. [Abstract 592].
22. Portier G., Elias D., Bouche O., et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. Journal of Clinical Oncology 2006, 24:4976-4982.
23. Mitry E., Fields A.L., Bleiberg H., et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. Journal of Clinical Oncology 2008, 26:4906-4911.
24. Parks R., Gonen M., Kemeny N., et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. Journal of the American College of Surgeons 2004, 753-761.
25. Kornprat P., Jarnagin W.R., Gonen M., et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Annals of Surgical Oncology 2007, 14:1151-1160.
26. Ychou M., Hohenberger W., Thezenas S., et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Annals of Oncology 2009, 20:1964-1970.
27. Van Cutsem E., Labianca R., Bodoky G., et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. Journal of Clinical Oncology 2009, 27:3117-3125.
28. Power D.G., Kemeny N.E. Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection. Crit Rev Oncol Hematol 2011, 79(September (3)):251-264.
29. Lorenz M., Muller H.H., Schramm H., et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer: German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Annals of Surgery 1998, 228:756-762.
30. Rudroff C., Altendorf-Hoffmann A., Stangl R., et al. Prospective randomised trial on adjuvant hepatic artery infusion chemotherapy after R0 resection of colorectal liver metastases. Langenbeck's Archives of Surgery 1999, 384:243-249.
31. Vauthey J.N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. Journal of Clinical Oncology 2006, 24:2065-2072.
32. Karoui M., Penna C., Amin-Hashem M., et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Annals of Surgery 2006, 243:1-7.
33. Ribero D., Wang H., Donadon M., et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007, 110:2761-2767.
34. Benoist S., Brouquet A., Penna C., et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?. Journal of Clinical Oncology 2006, 24:3939-3945.
35. Blazer D.G., Kishi Y., Maru D.M., et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. Journal of Clinical Oncology 2008, 26:5344-5351.
36. Adam R., Wicherts D.A., de Haas R.J., et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality?. Journal of Clinical Oncology 2008, 26:1635-1641.
37. Kishi Y., Zorzi D., Contreras C.M., et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Annals of Surgical Oncology 2010, 17(November (11)):2870-2876.
38. Chun Y.S., Vauthey J.N., Boonsirikamchai P., et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. Journal of American Medical Association 2009, 302:2338-2344.
39. Adam R., Pascal G., Castaing D., et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?. Annals of Surgery 2004, 240:1052-1061. [discussion 1054-61].